Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Authors||Yosuke Ota, Takeshi Otsubo, Junya Koroki, Yuko Hirose, Erina Koga-Yamakawa, Masashi Murata, Masashi Goto and Yasushi Matsuki|
|Title||Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody|
|Abstract Text||Cancer Res July 1 2018 (78) (13 Supplement) 4726|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DSP-0509||DSP 0509|DSP0509||DSP-0509 is a small molecule agonist of Toll-like receptor 7 (TLR7), which potentially inhibits tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 4726).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colon cancer||not applicable||DSP-0509 + unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, an anti-PD-1 inhibitor combined with DSP-0509 inhibited tumor growth in a syngeneic mouse model of colon cancer (Cancer Res July 1 2018 (78) (13 Supplement) 4726).||detail...|
|Unknown unknown||osteosarcoma||not applicable||DSP-0509||Preclinical||Actionable||In a preclinical study, DSP-0509 inhibited tumor growth and reduced metastatic lung nodules in a syngeneic mouse model of osteosarcoma (Cancer Res July 1 2018 (78) (13 Supplement) 4726).||detail...|